多巴胺作用药物对帕金森病患者上肢运动功能,力量和手的灵敏度的影响
Parisa Alaei1,2, Daryl J Wile3, Jennifer M Jakobi1,2
1Faculty of Health and Social Development, University of British Columbia Okanagan, Kelowna, BC, Canada.
Clinical parkinsonism & related disorders
|November 14, 2025
概括
多巴胺药物治疗显著改善了帕金森病 (PD) 患者的运动症状和手的灵敏度. 这些功能上的增长与肌肉强度的增加有关,而不是肌肉收缩性质的变化.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 康复医学 康复医学 康复医学
背景情况:
- 多巴胺类药物对于管理帕金森病 (PD) 的运动症状至关重要.
- 这些药物提高手的灵敏度的潜在机制尚不清楚,特别是关于肌肉收缩性质的机制.
研究的目的:
- 调查多巴胺药物对手的灵巧性,运动症状严重性和PD患者肌肉收缩性能的影响.
- 为了比较治疗 (ON) 与未治疗 (OFF) 药物状态中的运动功能和肌肉特征.
主要方法:
- 一项涉及16名患有PD的个体的研究,比较他们的表现在启动和关闭多巴胺类药物治疗.
- 评估了运动症状的严重程度 (MDS-UPDRS III),手的灵巧度 (Grooved Pegboard测试,Purdue Pegboard测试) 和肘部曲最大自愿收缩 (MVC).
- 评估了自愿激活和电气诱导的肌肉抽特性.
主要成果:
- 多巴胺作用药物显著改善了运动症状得分 (27%) 和手的灵敏度 (GPT: 11%,PPT: 34%).
- 随意最大收缩 (MVC) 在药物治疗后增加了4%,但电气诱导的收缩特性没有显著差异.
- 规范化的MVC与手的灵巧性表现相关,这表明力量的增加有助于功能改善.
结论:
- 多巴胺治疗增强了PD患者的运动症状和手的灵巧度.
- 手的功能性改善与肌肉强度的增加有关,独立于外围肌肉收缩性质的变化.
相关概念视频
Parkinson's Disease: Treatment
954
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
954
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


